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Abstract
Background: Combination antiretroviral treatment (cART) has been very successful, especially among selected patients in
clinical trials. The aim of this study was to describe outcomes of cART on the population level in a large national cohort.
Methods: Characteristics of participants of the Swiss HIV Cohort Study on stable cART at two semiannual visits in 2007 were
analyzed with respect to era of treatment initiation, number of previous virologically failed regimens and self reported
adherence. Starting ART in the mono/dual era before HIV-1 RNA assays became available was counted as one failed
regimen. Logistic regression was used to identify risk factors for virological failure between the two consecutive visits.
Results: Of 4541 patients 31.2% and 68.8% had initiated therapy in the mono/dual and cART era, respectively, and been on
treatment for a median of 11.7 vs. 5.7 years. At visit 1 in 2007, the mean number of previous failed regimens was 3.2 vs. 0.5
and the viral load was undetectable (,50 copies/ml) in 84.6% vs. 89.1% of the participants, respectively. Adjusted odds
ratios of a detectable viral load at visit 2 for participants from the mono/dual era with a history of 2 and 3, 4, .4 previous
failures compared to 1 were 0.9 (95% CI 0.4–1.7), 0.8 (0.4–1.6), 1.6 (0.8–3.2), 3.3 (1.7–6.6) respectively, and 2.3 (1.1–4.8) for.2
missed cART doses during the last month, compared to perfect adherence. From the cART era, odds ratios with a history of
1, 2 and .2 previous failures compared to none were 1.8 (95% CI 1.3–2.5), 2.8 (1.7–4.5) and 7.8 (4.5–13.5), respectively, and
2.8 (1.6–4.8) for .2 missed cART doses during the last month, compared to perfect adherence.
Conclusions: A higher number of previous virologically failed regimens, and imperfect adherence to therapy were
independent predictors of imminent virological failure.
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Introduction
Combination antiretroviral therapy (cART) has dramatically
reduced morbidity and mortality of HIV-infected persons
with access to care. Nevertheless, therapeutic failure still
remains substantial, in particular due to late initiation,
interruption or refusal of cART, incomplete adherence to
therapy, medication toxicities, antiretroviral drug resistance,
hepatitis virus co-infections, consumption of alcohol, illicit drug
use, or depression.
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The potency of ART regimens has continuously improved but
virological outcome is still not optimal. A large pan-European
collaboration recently published on responses to cART across age
groups and observed the best virological outcomes for older
patients with up to 80% having reached viral suppression to
,50 copies/ml by 3 years after initiating cART [1]. Recent
randomized controlled trials of cART in treatment-naive persons
showed viral suppression to ,50 copies/ml in up to 85% of study
participants at 48 weeks in intent-to-treat analyses [2–4].
Fortunately, significant progress has also been made among
treatment-experienced persons in whom rates of complete viral
suppression as high as 65% were reported at 48 weeks if new drug
classes were applied [5]. However, randomized trials are not
designed to generate long-term results and, because of generally
very selected, well motivated and closely monitored patient
groups, results from clinical trials are not readily applicable to
the general patient population.
Objectives
The aims of this study were to analyze determinants of virological
failure in all HIV-infected persons on cART prospectively followed
in a large national cohort study during 2007. Further, we wanted to
describe the frequency of treatment modifications and discontinu-
ations, as well as the clinical course. We were especially interested in
the history of previous treatment failures and adherence as
predictors for imminent virological failure.
Methods
Participants
We selected participants of the Swiss HIV Cohort Study
(SHCS) who were enrolled prior to 2007, were on uninterrupted
cART for $3 months at their first cohort visit in 2007 (visit 1); and
had one additional semiannual follow-up visit prior to June 30,
2008 (visit 2). Patients were categorized into two groups according
to the era of antiretroviral treatment initiation, i.e. mono/dual
drug therapy vs. cART era. We excluded patients who started with
drug combinations not clearly attributable to mono/dual drug
regimens or cART, unavailable CD4 cell counts, HIV-1 RNA or
adherence data within 6 months prior to visit 1 or at visit 2.
Description of Procedures or Investigations Undertaken
Patients were assigned to the mono/dual drug treatment era if
their initial regimen consisted of #2 nucleoside reverse-transcriptase
inhibitors (NRTI), or three NRTI’s without abacavir prior to 1999.
Patients starting with$3 drugs including a protease inhibitor (PI) or a
non-nucleoside reverse-transcriptase inhibitor (NNRTI) or abacavir
in addition to two other NRTI were assigned to the cART era.
Previous regimens were defined as virologically failing from the
date of the first available HIV-1 RNA record onward if $2
consecutive HIV-1 RNA measurements were .400 copies/ml, or
$1 measurement was.1000 copies/ml, while the patient was on the
same regimen for$3 months. In accordance with a UK-CHIC study
[6], any mono/dual drug regimen taken before cART was counted as
one additional failed regimen, because they were generally not
virologically suppressive and HIV-1 RNA was not routinely
measured at that time. Each individual treatment regimen was
counted only once as virologically failed, even if repeatedly used.
Self-reported adherence was classified according to the number
of missed doses within four weeks prior to a cohort visit (0, 1, 2, or
.2 missed doses) as described previously [7].
Hepatitis B virus (HBV) infection was considered active if HBs
antigen, HBe antigen or HBV DNA were positive. Hepatitis C
virus (HCV) infection was considered active if anti-HCV
antibodies and HCV RNA were positive; and inactive if HCV
serology was positive and HCV RNA negative.
Virological failure was defined as having a HIV-1 RNA
$50 copies/ml at visit 2. Treatment discontinuation was defined as
$15 days off cART between the two visits. Treatment modification
was recorded if at least one drug of a regimen was modified between
the two visits. Treatment interruptions lasting less than 15 days were
considered as treatment modifications. We also considered new AIDS-
defining clinical events or death occurring between the two visits.
Ethics
The SHCS is a prospective cohort study, established in 1988,
with semi-annual follow-up visits at university hospitals, collabo-
rating clinics or private physicians’ practices [8,9]. The protocol
was approved by all local ethical committees and all patients gave
written informed consent.
Statistical Methods (If Applicable)
We decided to perform separate analyses for patients who initiated
treatment in the mono/dual drug combination era and for patients
who started with cART because of the potential survivor bias in the
former group. Furthermore, preliminary analyses showed pronounced
interactions between era of starting ART and the impact of previously
failed regimens as well as the impact of suboptimal adherence. First,
we performed descriptive analyses of the proportion of patients with
HIV-1 RNA below and above 50 copies/ml and with CD4 cell
counts below and above 200/ml at visit 1, and analyzed the association
between these markers and the number of previous virologically failed
regimens. Second, we determined the virological status at visit 2, and
the proportion of patients with treatment discontinuation, treatment
modification or clinical progression to AIDS or death between visit 1
and 2. Third, we used uni- and multivariable logistic regression to
analyze predictors for virological failure at visit 2. Covariables in these
models included gender, age (grouped into ,40, 40–44, 45–49 and
50+ years), non-white ethnicity, mode of HIV transmission, HCV co-
infections, HIV-1 RNA (maximum ever, and ever ,50 copies/ml
prior to and at visit1), CD4 cell counts (nadir and at visit 1), adherence
to therapy, total duration of antiretroviral therapy (5 year strata) and
number of previous failed regimens. To assess whether the exclusion
of patients starting with non-standard ART affected our conclusions,
we performed a sensitivity analysis in which these patients were
combined with patients from the cART era. We used Stata 10.0
(StataCorp, College Station, Texas, USA).
Results
Patient Selection
The patient selection process is depicted in Figure 1. At their
first visit in 2007. 5473 patients were on ART. Of these 385 were
excluded because of non-standard initial drug regimens when
starting ART between 1995 and 1997, the years of transition from
mono/dual therapy to cART. 342 regimens were with single PI or
single NNRTI plus single NRTI and 43 with other non-standard
regimens. In addition, 547 patients were excluded due to various
reasons. Included and excluded patients were similar with regards
to gender, transmission risk group, CDC stage C at visit 1 (all
p.0.5). However, excluded patients were on average 1 year
younger (45 vs. 46 years, P = 0.003). The present analysis is thus
based on 4541 patients of whom 1419 (31.2%) initiated ART with
mono/dual therapies and 3122 (68.8%) with cART.
Patient Characteristics at Visit 1 (Table 1)
Reflecting the changing epidemiology of HIV in Switzerland,
patients who started with mono/dual treatments were more
Predicting Virological Failure
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frequently of white ethnicity, infected via needle sharing and thus
with active HCV co-infection, had higher CD4 cell counts at
enrolment in the SHCS, but lower nadir CD4 cell counts
thereafter. At visit 1, these patients had more advanced HIV
disease (74.3% vs. 52.6% in clinical CDC stages B or C), had
experienced more virologically failed regimens in the past (average
3.2 vs. 0.5), and the proportion with HIV-1 RNA ,50 copies/ml
was lower (84.6% vs. 89.1%). Irrespective of the era of treatment
initiation, higher numbers of previous failed regimens were
strongly associated with higher proportions of detectable HIV-1
RNA at visit 1 (chi-square test for linear trend, p,0.001) and of
CD4 cell counts ,200 cells/ml (p,0.001) at visit 1 (Figure 2).
Virological Outcome at Visit 2
Figure 3 depicts the virological course between the two visits.
The median time between the visits was 6.3 months (IQR: 5.8–
7.2). Of the patients with mono/dual treatment initiation, 15.4%
had a detectable viral load at visit 1. Among these, complete
suppression of viral replication was reached in 45.9% at visit 2.
Fewer patients (10.9%) who started with cART had a detectable
viral load at visit 1, and a higher percentage (62.5%) attained a
viral load ,50 copies/ml at visit 2 (p,0.001). On the other hand,
of those with undetectable viral load at visit 1, 6.7% in the mono/
dual vs. 5.9% in the cART group had a virologic failure with HIV-
1 RNA $50 copies/ml at visit 2 (P = 0.37).
Among all patients without treatment discontinuations between
the two visits, 179/1370 (13.1%) from the mono/dual and 271/
3039 (8.9%) from the cART era had HIV-1 RNA $50 copies/ml
at visit 2 (p,0.001). Results from uni- and multivariable logistic
regression analyses for both eras are shown in Figure 4. Virological
failures were independently associated with the number of
previous failed regimens, poor adherence, and lack of having ever
reached complete viral suppression. Adjusted estimates for the
number of previously failed regimen modeled as continuous
variables indicated a steeper association with virological failure in
patients from the cART era compared to the mono/dual era: odds
ratio per previous regimen failed of 1.87 (95% CI 1.58–2.21) vs.
1.49 (1.28–1.73). In addition, individuals of non-white ethnicity
from the cART era are more likely to have detectable viral load at
visit 2: adjusted odds ratio of 1.59 (1.09–2.31). This can be partly
explained by lower adherence levels among patients of non-white
ethnicity: perfect adherence was reported by 79.7% of non-white
vs. 82.7% (test for trend across adherence categories: P = 0.031).
The number of previously failed regimens remained a significant
predictor of virological outcome at visit 2 when limiting the analysis to
patients who had undetectable HIV-1 RNA levels at visit 1 with Odds
Ratios of 2.33 (1.18–4.62) for $5 previously failed regimens among
patients who started in the mono/dual era and 5.13 (2.62–10.0) for$3
previously failed regimens among patients who started in the cART era.
Results from a sensitivity analysis in which we included patients
who started with non-standard ART to the cART group were
virtually identical.
Treatment Discontinuations and Modifications
During the six months separating the two visits, 49/1419 (3.5%)
patients from the mono/dual era and 83/3122 (2.7%) patients from
the cART era discontinued treatment for 15 days or longer
(P = 0.14). Reasons for discontinuation were patient’s wish (69.4%
for patients from the mono/dual vs. 62.7% for patients from the
cART era) or physician’s decision (16.3% vs. 8.4%), drug toxicity
(4.1% vs. 8.4%), and others (10.2% vs. 20.5%). Treatment
modifications over the two consecutive visits were observed among
358/1419 (25.2%) patients from the mono/dual era and 768/3122
(24.6%) from the cART era (P = 0.65). 23/1419 (1.6%) patients
from the mono/dual era intensified treatment by adding a drug; the
other 335 (23.6%) stopped one or more drugs without completely
discontinuing treatment. Similarly, 47/3122 (1.5%) patients from
the cART era intensified treatment and 721/3122 (23.1%) stopped
taking at least one of the drugs. Reported reasons for stopping a
drug were virological, immunological, or clinical failure (9.0%
patients from the mono/dual vs. 4.7% from the cART era),
metabolic disorders (6.6% vs. 7.1%), gastro-intestinal disorders
Figure 1. The patient disposition for this study is based upon all patients seen in the Swiss HIV Cohort Study during 2007.
doi:10.1371/journal.pone.0008275.g001
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(2.4% vs. 2.8%), other toxicities (9.9% vs. 8.7%), or other reasons
such as patient’s wish or physician’s decision (72.1% vs. 76.7%).
Clinical Course
New clinical AIDS events between visit 1 and visit 2 occurred in 1
patient from the mono/dual era (non-Hodgkin lymphoma) and 4
patients from the cART era (3 non-Hodgkin lymphoma, 1
extrapulmonary tuberculosis). Not included in the above analyses are
the 33 patients who died before visit 2 (Figure 1). Of these, 15 had
initiated treatment in the mono/dual era and 18 in the cART era. For
4 patients the primary cause of death was attributed to HIV, 2
committed suicide, 1 died of an overdose of narcotics and for 5 patients
the causes of death were unknown. The causes of death for the
remaining 21 patients based upon ICD-10 codes were: 5 liver failures,
Table 1. Characteristics at the first semiannual follow-up visit in 2007 (visit 1) comparing individuals who started with mono/dual
ART and cART.
Category Subcategory mono/dual ART cART p-value1
Number of patients (%) 1419 (31.3) 3122 (68.7)
Sex (%) Female 398 (28.1) 947 (30.3) 0.118
Age – median years (IQR) 47 (43–53) 44 (38–50) ,0.001
Ethnicity (%) White 1281 (90.3) 2492 (79.8) ,0.001
Other 138 (9.7) 630 (20.2)
Transmission category (%) Heterosexual 402 (28.3) 1351 (43.3) ,0.001
Injecting Drug Use 393 (27.7) 464 (14.8)
Homosexual 571 (40.2) 1164 (37.3)
Other 53 (3.8) 143 (4.6)
Active hepatitis B co-infection (%) 89 (6.3) 171 (5.5) 0.285
Active hepatitis C co-infection (%) 356 (25.1) 459 (14.7) ,0.001
CD4 at cohort inclusion – median cells/ml (IQR) 340 (185–520) 304 (162–488) ,0.001
Nadir CD4 cell count – median cells/ml (IQR) 120 (48–204) 172 (78–257) ,0.001
Max. HIV-1 RNA - median log10 copies/ml (IQR) 5.0 (4.4–5.5) 5.1 (4.6–5.6) 0.004
Ever had undetectable viral load (%) 1374 (96.8) 3042 (97.4) 0.245
Clinical CDC Stage (%) A 365 (25.7) 1480 (47.4) ,0.001
B 597 (42.1) 805 (25.8)
C 457 (32.2) 837 (26.8)
CD4 cell count – median cells/ml (IQR) 492 (353–696) 496 (353–680) 0.981
HIV-1 RNA ,50 (%) 1201 (84.6) 2781 (89.1) ,0.001
ART regimen (%) 3 NRTI only 63 (4.4) 309 (9.9) ,0.001
Unboosted PI based 108 (7.6) 187 (6.0)
Boosted PI based 554 (39.0) 1174 (37.6)
NNRTI based 344 (24.2) 1279 (41.0)
3 class regimen 215 (15.2) 93 (3.0)
Any drug + T-20 59 (4.2) 13 (0.4)
Other 76 (5.4) 67 (2.1)
Total ART duration (years) – median years (IQR) 11.7 (10.9–13.8) 5.7 (2.8–8.7) ,0.001
Adherence (in the past 4 weeks, %) Never missed a dose 1158 (81.6) 2574 (82.5) 0.024
Missed 1 dose 152 (10.7) 376 (12.0)
Missed 2 doses 54 (3.8) 79 (2.5)
Missed .2 doses 55 (3.9) 93 (3.0)
Number of ART regimens previously failed (%) 0 - 2 2079 (66.6) ,0.001
1 191 (13.5) 728 (23.3)
2 403 (28.4) 211 (6.8)
3 338 (23.8) 63 (2.0)
4 231 (16.3) 22 (0.7)
$5 256 (18.0) 19 (0.6)
mean – (range) 3.2 (1–14) 0.5 (0–8) ,0.001
1P-values for comparison of mono/dual and cART era are calculated from chi-square tests (categorical variables) or from Wilcoxon-Mann-Whitney tests (continuous variables).
2By definition, one failure event was added to all patients from the mono/dual era. Therefore, no patients from the mono/dual era can have 0 regimen previously failed.
doi:10.1371/journal.pone.0008275.t001
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2 liver carcinoma, 1 gastrointestinal haemorrhage, 2 acute peritonitis, 4
lung cancers, 1 breast cancer, 2 pneumonia, 2 septicemia and 2
cardiovascular events.
Discussion
We studied the impact of patients’ treatment history, previous
virological failures and adherence at two semiannual visits in
2007/08 among a cohort of 4541 participants on stable cART. At
visit 1 the percentage of patients with viral loads ,50 copies/ml
was high with 84.6% of patients who started ART in the mono or
dual therapy era and 89.1% among those who started with cART
directly. Nevertheless, between 5 and 7% of these successfully
treated patients experienced virological failure until visit 2 after six
months. In the analysis of predictors for virological failure at visit 2
we found that the main independent risk factors were the number
of previous failed regimens, suboptimal adherence to therapy and
never having achieved an undetectable viral load.
We observed that approximately 3% of patients discontinued
treatment for 2 weeks or longer and 25% modified treatment
between the two semiannual visits. A recent study investigating
treatment switches and interruptions in the SHCS showed that
changes are frequent: up to 48% of the patients change treatment
within 12 months after treatment initiation. Intolerance is the
main reason for treatment switches, whereas discontinuation is
equally explained by both intolerance and patient’s wish [10].
The proportion of 85–90% of treated patients in routine clinical
care having undetectable viral loads is similar to what has been shown
for randomized clinical trials of treatment naive patients
[2–4]. In contrast to clinical trials which usually have stringent
inclusion and exclusion criteria, patients in our study are largely
unselected and representative. In fact, a comparison of drug sales data
for Switzerland (Source: IMS Health GmbH, Sonnenbergstrasse 11,
6052 Hergiswil, Switzerland) with treatment data of the SHCS for
2007 showed that 74% of the NRTI compounds sold in the country
had been consumed by individuals followed in the SHCS.
Figure 2. Distribution of viral loads and CD4 cell counts at first follow-up visit in 2007 (visit 1) according to the number of previous
virologically failed regimens. The upper panels show HIV-1 RNA counts for patients who started therapy in the mono/dual era (A) and in the cART
era (B). Lower panels show CD4 cell counts for patients from the mono/dual era (C) and for patients from the cART era (D), respectively. By definition all
patients from the mono/dual era failed at least one regimen.
doi:10.1371/journal.pone.0008275.g002
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Few long-term studies have directly compared patients from the
mono/dual treatment and the cART era. The distinct group of
patients, who started treatment already in the pre-cART era and
survived, has now been on cART for more than 10 years. Most of
these patients were only on partially suppressive treatments before
cART [11], which influenced the course of their HIV infection
[12,13]. Many of them also experienced virological failure on
cART regimens taken thereafter. Archived resistance mutations
can lead to treatment failure of subsequent regimens [14], and
therefore, further treatment options are compromised. In 1999,
three years after cART was routinely available, we observed a
worse virological outcome among patients who had been pre-
treated with mono/dual therapies with .35% viral rebounds, vs.
20% for those who initiated therapy with cART [9]. In the
EuroSida study, six years after treatment initiation, up to 20% of
the patients experienced multiple drug class failure which was
associated with poorer clinical status [15]. A more recent multi-
cohort analysis showed that the risk for virological failure was
reduced by at least 50 percent between 1996 and 2002 among
treatment-naı¨ve persons starting cART [16].
The association between the history of treatment failures
and later viral break-through has been shown in previous
studies [6,17]. Prior virologic failure doubled the risk of
subsequent virologic failure in a cross-sectional study [17], and
viral rebound rates were associated with the number of
regimens previously failed, the risk increasing by 38% for
each failed regimen [6]. It is likely that HIV-1 resistance
mutations had been accumulated in such patients with
repetitive virological failures but a resistance test at visit 1
would not have been feasible in the vast majority of patients
due to suppressed viral replication.
Although the assessment of adherence is not uniform and
subject to methodological bias, the relationship between poor
adherence and virological failure is not disputed [7,18,19]. The
SHCS documents self-reported adherence within the previous
month, which was found to reliably correlate with viral rebounds
[7,20]. Adherence may differ between regimens and once-daily
regimens may be less forgiving. However, due to small numbers of
patients on once-daily treatments further analyses were not
possible in the present study. We cannot fully explain the impact
of ethnicity on virological failure in our study because migrants
have unrestricted access to care and medication in our country
[21]. However, we assume that socio-economic status which is
often lower in migrant population in Switzerland, as well as
psychosocial and language barriers negatively affect adherence
and treatment outcomes [18], as has been observed in other
European cohorts [6,22].
Limitations
The design of the present study implied that patients had to
survive until 2007, therefore selecting patients with good
prognostic markers who initiated ART in the era of mono/
dual therapies. In fact, 2688/5769 (47%) patients who initiated
ART with a mono/dual regimen in the SHCS died before
2007, vs. only 349/5191 (6.7%) patients who started therapy
with cART. Our study reflects the current situation of the
present heterogeneous patient population in a country with
universal access to care. Thus, extrapolations to other settings,
especially in developing countries need to be done with
caution. An additional limitation by design is the short
observation period of 6 months which precludes the analysis
of events that require a longer time to occur. On the other
hand, this relatively short follow-up period was deemed to
represent the typical clinical situation of routine patient care.
Conclusions
Although antiretroviral treatment is very successful, lack of
continued viral suppression on stable cART is still relatively
Figure 3. Virological course between the first follow-up visit in 2007 (visit 1) and the next semi-annual follow-up cohort visit (visit
2). Viral loads patterns are shown in the upper panels: (A) patients from the mono/dual ART era; (B) patients from the cART era.
doi:10.1371/journal.pone.0008275.g003
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frequent in today’s practice. Major information on risks for
virological failure is the accurate patient’s history, including
the history of mono/dual drug therapy, the number of
previous regimens with virological failure, and adherence to
therapy. The former factors are associated with archived
resistance mutations and mandate a careful selection of drugs
in case of a treatment change, even if the current resistance
testing - if at all possible - may not reveal all accumulated
resistance mutations. Maintenance of good adherence to
therapy is key of patient care and long-term suppression of
viral replication, especially with the promising new drugs and
drug classes currently entering routine care.
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